XML 75 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders' Equity (Details)
 12 Months Ended
Jul. 24, 2023
USD ($)
$ / shares
shares
Jul. 15, 2022
USD ($)
$ / shares
shares
May 21, 2020
USD ($)
$ / shares
shares
Sep. 06, 2018
$ / shares
shares
May 21, 2018
$ / shares
shares
Jan. 04, 2018
USD ($)
Dec. 03, 2015
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
vote
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
May 03, 2024
USD ($)
day
Stockholders Equity Deficit [Line Items]                      
Common stock, voting right per share | vote               1      
Issuance of common stock (in shares) | shares     9,433,963                
Offering price (in dollars per share) | $ / shares     $ 13.25                
Cash flows from financing activities     $ 117,100,000                
Payments of stock issuance costs   $ 200,000                  
Warrant term 5 years                    
Proceeds from issuance of private placement $ 212,100,000             $ 0 $ 201,323,000 $ 119,946,000  
Issuance of common stock                 $ 201,323,000 $ 119,946,000  
Shares of common stock, repurchase (in shares) | shares               0      
Founder                      
Stockholders Equity Deficit [Line Items]                      
Issuance of common stock (in shares) | shares       1,795,023 251,547            
Issuance price per share (in dollars per share) | $ / shares       $ 9.63 $ 2.61            
Percentage of fully diluted share capital           15.00%          
Increased in equity capital amount           $ 300,000,000.0          
Additional shares of restricted stock subject to vesting restrictions (in shares) | shares       1,795,023 251,547            
Founder Shares                      
Stockholders Equity Deficit [Line Items]                      
Issuance of common stock (in shares) | shares             9,160,888        
Issuance price per share (in dollars per share) | $ / shares             $ 0.0001        
Issuance of common stock             $ 4,100        
Common stock vesting percentage           50.00%          
Common stock vesting period           5 years          
Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.                      
Stockholders Equity Deficit [Line Items]                      
Tender offer or exchange offer, percentage of shares outstanding                     50.00%
Purchase price of each share subject to equity option, percentage of daily volume-weighted average per share price                     107.50%
Purchase price of each share subject to equity option, number of trading days | day                     30
Purchase price of each share subject to equity option, minimum price threshold (in dollars per share)                     163.00%
Contract with customer, liability, fair value of equity option                     $ 500,000
Maximum | Chiesi Farmaceutici S.p.A And Chiesi USA, Inc.                      
Stockholders Equity Deficit [Line Items]                      
Equity option owned by chiesi                     9.90%
Private Placement                      
Stockholders Equity Deficit [Line Items]                      
Offering price (in dollars per share) | $ / shares $ 1.63125 $ 7.21                  
Shares issued in transition (in shares) | shares 129,869,440 16,649,365                  
Net proceeds, after deducting underwriting discounts, commissions, and offering expenses   $ 120,100,000                  
Payments of stock issuance costs $ 10,800,000                    
Exercise price of warrants (in dollars per share) | $ / shares $ 2.04                    
Warrant term 5 years                    
Private Placement | Officer, Director, Employee Or Consultant                      
Stockholders Equity Deficit [Line Items]                      
Offering price (in dollars per share) | $ / shares $ 1.85125                    
Private Placement | Maximum                      
Stockholders Equity Deficit [Line Items]                      
Number of warrants (in shares) | shares 32,467,360